NEW YORK (dpa-AFX) – The possible preliminary out of vaccinations with the active ingredient from Johnson & Johnson (JohnsonJohnson) (J&J) in the USA put a little strain on the Dow Jones Industrial (Dow Jones 30 Industrial) on Tuesday. The US leading index fell 0.41 percent to 33,608 points. The shares of Johnson & Johnson (JohnsonJohnson) were among the biggest losers in the Dow with minus two percent. The technology-heavy Nasdaq exchange, on the other hand, set new records.
Following reports of sinus vein thrombosis that occurred after vaccination with the active ingredient from Johnson & Johnson in the USA, the responsible US authorities recommended a temporary suspension of vaccinations. This will probably only be maintained for a few days. The US pharmaceutical company is also postponing the launch of the vaccine in Europe.
In contrast to the Dow, the NASDAQ 100 rose 0.97 percent to 13,953 points and reached another record high. The next round mark of 14,000 points is getting closer and closer. The index was driven by the two heavyweights Tesla and Apple. For the market-wide S&P 500 it went up 0.16 percent to 4135 points – also to a record high.
While Johnson & Johnson’s share price fell, the stocks of its competitors in the global corona vaccine business, Biontech (BioNTech (ADRs)) and Moderna, rose 5.1 percent and 6.6 percent, respectively.
The Dow Jones Industrial was also burdened by the price losses of Goldman Sachs and JPMorgan (JPMorgan ChaseCo) of more than one percent each. Both investment banks will publish their reports on the first quarter of the business on Wednesday before the starting bell.
At American Airlines, the news that the airline expects an adjusted loss of 2.8 billion US dollars for the first quarter caused a price loss of three percent./bek/he
–
TRADE FOREIGN EXCHANGE WITH UP TO LEVER 30 NOW
Trade forex with high leverage and small spreads. With only € 100.00 you can benefit from the effect of € 3,000 in capital.
–
76.4% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you can afford the high risk of losing your money.
–
– .
